← United States · Coverage record
US · SEC FORM 4
Evolus, Inc.
EOLS · Nasdaq · CIK 0001570562 · Healthcare · Drug Manufacturers—Specialty & Generic
INSIDER SIGNAL
0 qualifying P purchase groups
in the current 180-day scoring window
1 Form 4 transaction lines observed in the same window
1 sales · 0 option, withholding, award, gift or other lines
WHY NO ACTIVE SIGNAL?
Score anatomy
No score is calculated because there is no qualifying purchase in the active window. Unavailable inputs are not treated as zero or as a bearish signal.
Why is there no score?
- No qualifying open-market purchase supplies cluster, size, role, recency or conviction inputs.
- Sales and other Form 4 activity remain visible as context and do not create a negative score.
Sales and other Form 4 activity are shown separately and do not create a negative buy signal. Absence of buying is not scored as bearish.
Insider activity timeline
Owner lanes show the latest 180 days. Symbol shape identifies the transaction type; sales remain context only.
—
Purchase breadth, concentration & cluster buying
These modules activate when qualifying purchases enter the 180-day research window.
SIGNAL HISTORY
Scores are archived only when the company qualifies for a published US buy-signal snapshot. Last qualifying purchase: 2025-08-15 · Stewart Brady.
Recent Form 4 activity
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
Market context
Market context has not been captured for this ticker yet. The daily market-context job processes the US universe in rotating batches.
Short interest
Short interest is external context reported to FINRA by broker-dealers. It does not affect the Insider Signal.
- Shares short
- 5,628,168
- Previous report
- 5,530,759
- Avg daily volume
- 603,494
- Days to cover
- 9.3
FINRA settlement date: 2026-09-30 · Captured 2026-10-12 · FINRA equity short interest ↗. A share count, published about a week after each of two settlement dates a month; not a percentage of shares outstanding.
Historical equity purchases
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2025-08-15 | Stewart Brady | Purchase (P) | Common Stock | 30,000 | USD 6.82 | USD 204,600 | SEC filing ↗ |
| 2025-06-09 | White Albert G III | Purchase (P) | Common Stock | 20,000 | USD 9.45 | USD 189,000 | SEC filing ↗ |
| 2023-08-15 | Malik Vikram | Purchase (P) | Common Stock | 174,967 | USD 7.41 | USD 1,296,505 | SEC filing ↗ |
| 2022-09-12 | HAYMAN ROBERT | Purchase (P) | Common Stock | 1,091 | USD 10.78 | USD 11,761 | SEC filing ↗ |
| 2022-09-09 | HAYMAN ROBERT | Purchase (P) | Common Stock | 8,909 | USD 10.35 | USD 92,208 | SEC filing ↗ |
| 2022-09-07 | HAYMAN ROBERT | Purchase (P) | Common Stock | 5,000 | USD 10.05 | USD 50,250 | SEC filing ↗ |
| 2022-09-07 | HAYMAN ROBERT | Purchase (P) | Common Stock | 4,967 | USD 10.05 | USD 49,918 | SEC filing ↗ |
| 2022-09-06 | BLANK SIMONE | Purchase (P) | Common Stock | 20,000 | USD 9.24 | USD 184,800 | SEC filing ↗ |
| 2022-09-06 | FARRELL PETER C | Purchase (P) | Common Stock | 10,000 | USD 9.10 | USD 91,000 | SEC filing ↗ |
| 2021-08-27 | Medytox Inc. | Purchase (P) | Common Stock, $0.00001 par value per share | 51,000 | USD 10.93 | USD 557,430 | SEC filing ↗ |
| 2021-08-26 | Medytox Inc. | Purchase (P) | Common Stock, $0.00001 par value per share | 66,000 | USD 11.02 | USD 727,320 | SEC filing ↗ |
| 2021-08-25 | Medytox Inc. | Purchase (P) | Common Stock, $0.00001 par value per share | 44,000 | USD 11.12 | USD 489,280 | SEC filing ↗ |
| 2021-08-24 | Medytox Inc. | Purchase (P) | Common Stock, $0.00001 par value per share | 72,219 | USD 11.17 | USD 806,686 | SEC filing ↗ |
| 2021-08-23 | Medytox Inc. | Purchase (P) | Common Stock, $0.00001 par value per share | 69,781 | USD 11.03 | USD 769,684 | SEC filing ↗ |
| 2021-08-20 | Medytox Inc. | Purchase (P) | Common Stock, $0.00001 par value per share | 48,000 | USD 10.56 | USD 506,880 | SEC filing ↗ |
Form 4 evidence
17 transaction lines in the latest 365-day window; 206 in local history.
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | MOATAZEDI DAVID | Sale (S) | Common Stock | 105,108 | USD 9.04 | USD 950,176 | SEC filing ↗ |
| 2026-03-20 | MOATAZEDI DAVID | Sale (S) | Common Stock | 13,669 | USD 4.75 | USD 64,928 | SEC filing ↗ |
| 2026-03-20 | Avelar Rui | Sale (S) | Common Stock | 3,119 | USD 4.75 | USD 14,815 | SEC filing ↗ |
Show recent Form 4 evidence (17 grouped rows)
| Date | Owner | Type | Security | Shares | Avg. price | Approx. value | Source |
|---|---|---|---|---|---|---|---|
| 2026-09-02 | MOATAZEDI DAVID | Sale (S) | Common Stock | 105,108 | USD 9.04 | USD 950,176 | SEC filing ↗ |
| 2026-03-20 | MOATAZEDI DAVID | Sale (S) | Common Stock | 13,669 | USD 4.75 | USD 64,928 | SEC filing ↗ |
| 2026-03-20 | Avelar Rui | Sale (S) | Common Stock | 3,119 | USD 4.75 | USD 14,815 | SEC filing ↗ |
| 2026-03-17 | MOATAZEDI DAVID | Sale (S) | Common Stock | 116,720 | USD 4.89 | USD 570,761 | SEC filing ↗ |
| 2026-03-17 | Avelar Rui | Sale (S) | Common Stock | 29,996 | USD 4.89 | USD 146,680 | SEC filing ↗ |
| 2026-03-16 | MOATAZEDI DAVID | Option exercise / conversion (M) | Common Stock | 67,489 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-03-16 | Avelar Rui | Option exercise / conversion (M) | Common Stock | 8,804 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-17 | White Albert G III | Award / grant (A) | Common Stock | 45,559 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-17 | Stewart Brady | Award / grant (A) | Common Stock | 45,559 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-17 | Parschauer Karah Herdman | Award / grant (A) | Common Stock | 45,559 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-17 | Mitchell Tatjana | Award / grant (A) | Common Stock | 121,489 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-17 | Malik Vikram | Award / grant (A) | Common Stock | 45,559 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-17 | MOATAZEDI DAVID | Award / grant (A) | Common Stock | 313,212 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-17 | GILL DAVID N | Award / grant (A) | Common Stock | 45,559 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2026-02-17 | Avelar Rui | Award / grant (A) | Common Stock | 94,913 | USD 0.00 | USD 0 | SEC filing ↗ |
| 2025-12-22 | MOATAZEDI DAVID | Sale (S) | Common Stock | 10,539 | USD 7.15 | USD 75,354 | SEC filing ↗ |
| 2025-12-22 | Avelar Rui | Sale (S) | Common Stock | 2,261 | USD 7.15 | USD 16,166 | SEC filing ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
Snapshot & identity
| Snapshot date | 2026-10-18 |
|---|---|
| Ranking version | US-v1.2 |
| Data quality | PASS ELIGIBLE · — |
| Ticker | EOLS |
| CIK | 0001570562 |
| Sector | Healthcare |
| Industry | Drug Manufacturers—Specialty & Generic Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| Exchange | Nasdaq |
Data coverage
| Local Form 4 history | 206 transaction lines from 2020-01-07 to 2026-09-02 24 P purchase lines · 92 S sale lines · 90 other lines |
|---|---|
| SEC company submissions | Open SEC filings ↗ |
Local ledger as of 2026-10-18. Mapping status is an audit field and does not erase SEC filing evidence.